Chief Executive Officer
Pascal PRIGENT holds a Master of Business Administration from INSEAD (1995) and is a graduate of Reims Business School (1989). Prior to joining GENFIT as our Executive Vice President, Marketing and Development, he was Vice President Marketing-U.S. Vaccines for GlaxoSmithKline USA from April 2014 to November 2017. Prior to this, he was Vice President and General Manager of GlaxoSmithKline Romania from January 2011 to March 2014. He also served in various roles at Eli Lilly and its affiliates from 1996 through January 2011. Pascal is GENFIT’s CEO, effective on September 16, 2019.
Chief Scientific Officer
Dean HUM earned a Ph.D. in Biochemistry from McGill University in Montreal in 1990. An expert in the modulation of transcription factors and nuclear receptors associated with endocrine and cardiometabolic diseases, he held a research position at the University of California in San Francisco before becoming a Professor at Laval University in Quebec. He joined GENFIT in 2000 as Chief Scientific Officer. Dean Hum is today a key person in the organization of GENFIT. In particular, he is responsible for defining, implementing, employing and coordinating short-, medium- and long-term strategies relating to R&D programs and portfolio. He coordinates all R&D activities with the CEO and in close collaboration with scientific officers and project managers. He is also a president and member of the board of directors of our wholly owned subsidiary, GENFIT Corp., and a member of the Management Committee of our wholly owned subsidiary GENFIT Pharmaceuticals SAS.
Chief Operating Officer
Pascal Caisey joined GENFIT in September 2019 as Executive Vice President of Commercial Development, becoming Chief Commercial Officer in January 2021 and was appointed Chief Operating Officer in March 2022. He has vast pharmaceutical business experience, holding roles with GSK, BMS, Pfizer, Schering Plough and most recently Boehringer Ingelheim, where he oversaw, as the European Business Manager, the commercial launch of empagliflozin in Europe. Mr. Caisey is a registered nurse and holds an MBA from École des Hautes Études Commerciales (HEC) in Paris
Chief Medical Officer
Carol ADDY holds an M.D. degree from the University of Massachusetts Medical School and a Master of Medical Science degree from Harvard Medical School. She has over 30 years working in the healthcare and wellness space, including leading clinical development teams in the pharmaceutical industry (Merck) and supporting life-cycle management of approved therapies for obesity. Prior to joining GENFIT, she was Chief Medical Officer at HMR Weight Management Services Corp., a wholly owned subsidiary of Merck. Carol is GENFIT’s CMO, effective on September 2, 2019
Chief Financial Officer
Thomas BAETZ graduated from ESCP Europe and earned a MSc. in Finance and Actuarial Science from the École Nationale Supérieure de la Statistique et de l’Administration Économique (ENSAE). He has 18 years of extensive global experience in corporate finance and investment, acquired in both start-ups and publicly listed companies specialized in healthcare and technology, including two years in the United-States and seven years in China. Thomas served as our Chief Financial Officer since April 1, 2021. Prior to that he was Director of Healthcare at Dragon Financial Partners, where he advised European healthtech companies on licensing agreements, fundraising and operational management. Previously, he spent four years as CFO and Head of Asia-Pacific at the innovative medtech Impeto Medical in Paris and Hong-Kong. He held leadership positions in finance at Cegedim for 10 years, managing the financial control and leading the financial integration during its acquisition of Dendrite.
EVP, Data & Information Technology
John Brozek holds three master’s degrees respectively in Cell and Molecular Biology from Lille University, Bioinformatics from Paris 7 University and Information Technology from Amiens University. He started his career in 2001 as Bioinformatician with IT-omics, a startup specializing in Information Systems design and data mining for biotech companies. In 2005, he joined GENFIT where he progressively took the lead of In Silico activities providing support in bioinformatics, biostatistics and Information Systems design. Since 2016, in addition to managing the In Silico activities, he leads the IT Department where he has been focusing on a global Information System renewal project while continuing to develop data related project (data science and business intelligence). His appointment to the Executive Committee reflects our conviction that data and information technology challenges will be critical to the future success of biotech companies.
EVP, Human Resources
Emilie Desodt joined GENFIT in January 2018 as Human Resources Director. Emilie has been working in Human Resources for the past 18 years in various operational and strategic positions. Prior to joining GENFIT 4 years ago, Emilie was in charge of HR activities, first at regional level (Americas & Middle East) then at global level at the Lesaffre Group. She has also held various HR roles of increasing responsibilities within General Electric. Emilie holds a bachelor’s degree in computer sciences (MIAGE) and a master’s degree in HR Development. Her appointment to the EXCOM as EVP, Human Resources, shows GENFIT’s commitment to continuously improving motivation, professional development and performance of our employees.
Corporate Secretary, Director of Legal Affairs
Laurent LANNOO graduated from the University of Lille law school with a degree in Business Law (DESS Juriste d’Entreprise). He began his professional career at M&M, a consulting firm, in 1994, becoming partner in 1996. One of the consulting projects led him to join Eurasanté, the public agency for the economic development of healthcare activities in the Nord – Pas de Calais region of France in 1995, where he was in charge of finance and administration from 1996 to 2005. Thereafter, he was the Corporate Secretary of the Cœur et Artères foundation and chairman of its executive board from 2005 to 2008. In 2008, he joined GENFIT as Corporate Secretary and Director of Legal Affairs.
Chief Compliance Officer, EVP International Legal Affairs
Stefanie MAGNER joined GENFIT in March 2016 as Deputy Director of Legal Affairs. Prior to joining GENFIT, she spent nearly 10 years at the Paris offices of the global U.S. law firm, Jones Day advising issuers, many in the biotech space, and banks on a variety of corporate, cross-border securities and M&A transactions, including several U.S. IPOs. She is admitted to practice law in New York and is a former member of the Paris Bar. She graduated from the University of Pennsylvania with a Bachelor of Arts in International Relations and French, as well as an international diploma from Sciences-Po Paris. She received her U.S. law degree from Washington College of Law at the American University in Washington D.C. and holds a Masters of Business Litigation from the Université de Paris X – Nanterre. Stefanie holds the position of Chief Compliance Officer, EVP International Legal Affairs since March 1, 2021.
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
Jean-Christophe MARCOUX is an engineer, and graduated from INSA Lyon in France, having spent part of his time at the University of Leeds in England, and also holds a degree in Strategic Management and Economic Intelligence from EGE in France. For nearly 15 years, he led international projects and programs in a variety of industrial sectors, in particular in Europe and Asia, and with client and colleagues in the United States. In 2012, he joined IMS Health, now IQVIA, the leading global information and technology services company providing clients in the healthcare industry, where he lead projects in healthcare systems: patient longitudinal studies, forecasting, targeting, profiling, prospective analyses, digital healthcare and innovation. He joined GENFIT at the end of 2015 to play a cross-disciplinary role regarding tactical, strategic and operational matters and was named Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG at the end of 2016
Chief Technology Officer
Meriam KABBAJ is pharmacist by training (University of Geneva) and received her Master and PhD in Pharmaceutical Sciences from the University of Montreal. She acquired clinical drug development experience and was exposed to quality assurance and regulatory affairs in a leading Contract Research Organization (Celerion, formerly MDS Pharma Sciences) specialized in applied translational medicine, where she held many key operational and leadership positions. After a 10 year-deep dive in the pharmaceutical industry, she co-founded Versantis where she successfully led the development of VS-01 from an academic prototype to a clinical lead compound and supported the fundraising activities. As a result of the acquisition of Versantis by GENFIT in September 2022, Meriam joined the Executive Committee as Chief Technology Officer in charge of CMC, Analytical Chemistry and Non-Clinical Development activities.
EVP Research & Translational Science
Sakina Sayah-Jeanne joined GENFIT on April 3rd, 2023 as Executive Vice-President Research & Translational Science , member of the Executive Committee. Sakina has more 20 years pharmaceutical industry experience, including 7 years at GENFIT. Sakina obtained her PhD in Molecular and Cellular Biology in 1998, specializing in Neuro-Immunology, at the University of Rouen (Role of the complement in central nervous system pathologies with an inflammatory component). In 1999, Sakina joined Innothera, a French pharmaceutical group, as Project Leader, Pharmacology (Neurogenic pain). In 2002, Sakina joined GABA Laboratoire, as Scientific Attaché (oral and dental care). Sakina joined GENFIT in 2003 as a Project Leader, Preclinical. She then became Director of Therapeutic Target Research in 2005 (Cardiometabolic diseases, Alzheimer’s disease). In 2011, Sakina joined DaVolterra as the Manager of the Preclinical Research, to define and manage the nonclinical strategy for mechanistic and proof-of-concept studies for the product under development (Gut microbiome protection for the prevention of infectious diseases). In 2015, she was appointed Senior Director, Translational and Transversal R&D, where she was in charge of producing decision support for clinical development of the product, addressing questions around dose regimen and safe use for the different indications and populations, developing argumentations and defending Sponsor’s position statements with regulatory authorities (Gut microbiome protection for (i) prevention of infectious diseases, (ii) efficacy of anti-cancer treatments).
Tom Huijbers joined GENFIT on March 13, 2023 as Executive Vice-President Regulatory, member of the Executive Committee. Tom has more than 20 years of experience in the pharmaceutical industry. In 1999, he graduated with a Master of Science in Medicinal Chemistry and Molecular Pharmacology, from the University of Groningen (Netherlands). The same year, he joined the Janssen Research Foundation (Belgium) as Associate Manager Regulatory Affairs. In 2004, he joined Grünenthal GmbH based in Germany, as Regulatory Affairs Manager. As of 2006, he became Senior Regulatory Affairs Manager before holding the positions of Associate Director Global Regulatory Affairs, then Senior Director Global Regulatory Affairs between 2009 and 2018. In 2018, Tom became Vice President, Head Development Strategy & Intelligence in Grünenthal’s Innovation Unit Devices and Technologies. Before joining GENFIT, Tom had worked since 2020 at Pinney Associates (USA) and Harm Reduction Therapeutics (USA), as an Independant Regulatory Affairs Consultant.